Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As a result, the CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I axis was identified as a bottleneck in the miRNA-mediated gene expression regulatory network of PCa according to network topological analysis.
|
29467540 |
2018 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The MDM2 oncogene is overexpressed in many human cancers, including sarcomas, certain hematologic malignancies, and breast, colon and prostate cancers.
|
15720189 |
2005 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.
|
23187804 |
2012 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, by enhancing the expression of Mdm2, the uncharacterized 280B protein provides a novel mechanism of p53 suppression in prostate cancer.
|
24236047 |
2013 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
The identification of the alternative reading frame protein (ARF) / murine double minute protein (MDM2) / p53 tumour suppressor pathway potentially involving the IL-6/STAT3 axis as a restricting factor in prostate cancer deficient in the tumour suppressor phosphatase and tensin homologue (PTEN) opened new avenues to currently available therapies.
|
26691865 |
2015 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We find that USP12 deubiquitinates MDM2 and AR, which in turn controls the levels of the TP53 tumour suppressor and AR oncogene in prostate cancer.
|
29755129 |
2018 |
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that TP53 and MDM2 polymorphisms play a role in PCa susceptibility in southern Chinese Han population.
|
20875869 |
2010 |
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
|
22119201 |
2012 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results indicate that cisplatin-chemotherapy in combination with targeting the MDM2/p53 axis is an attractive strategy to treat prostate cancer.
|
23726840 |
2013 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.
|
19470936 |
2009 |
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although p53-inactivating mutations have been described in the majority of human cancers, their role in prostate cancer is controversial as mutations are uncommon, particularly in early lesions. p53 is activated by hypoxia and other stressors and is primarily regulated by the Mdm2 protein.
|
15550400 |
2005 |
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study was to evaluate the relationship between single-nucleotide polymorphism (SNP) rs2228001 in xeroderma pigmentosum group C (XPC), SNP rs4073 in interleukin 8 (IL8), and SNP rs2279744 in mouse double minute 2 (MDM2) homolog gene with PCa susceptibility.
|
26135929 |
2015 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates that small molecule MDM2 antagonists might be useful in the treatment of human prostate cancers that retain functional p53 and androgen receptor signaling.
|
17440969 |
2007 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The deubiquitinating enzyme USP2a has shown oncogenic properties in many cancer types by impairing ubiquitination of FASN, MDM2, MDMX or Aurora A. Aberrant expression of USP2a has been linked to progression of human tumors, particularly prostate cancer.
|
22370483 |
2012 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination.
|
14751501 |
2004 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have previously shown in separate studies that MDM2 knockdown via antisense MDM2 (AS-MDM2) and E2F1 overexpression via adenoviral-mediated E2F1 (Ad-E2F1) sensitized prostate cancer cells to radiation.
|
19010821 |
2008 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We report here that p53 mutations occur in approximately one third of early stage prostate cancers and that expression of HPV E6 or over-expression of mdm2 contributes to loss of p53 function in an additional 25% of organ-confined disease.
|
14503938 |
2003 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antisense anti-human-MDM2 mixed-backbone oligonucleotide and its mismatch control were tested in in vitro and in vivo human prostate cancer models (LNCaP, DU 145, and PC-3) for anti-tumor activity.
|
12518324 |
2003 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, our results indicate that combinatorial inhibition of MDM2 and MDMX may offer a novel compelling strategy for prostate cancer therapy.
|
29464071 |
2018 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Studies on Radiation Therapy Oncology Group tissue samples have identified aberrant expression of p53, MDM2 (an E3 ubiquitin ligase that targets p53 for proteosomal degradation), and p16 (an upstream regulator of retinoblastoma and hence E2F1 in prostate cancer); abnormal expression of these biomarkers has been associated with clinical outcome after radiotherapy ± androgen deprivation therapy.
|
20832018 |
2010 |
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer.
|
28454424 |
2017 |
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lastly, variants within MDM2 and CCNG1 were protective for aggressive PCa in both ethnic groups.
|
26708993 |
2016 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
We propose that UGT2B28, UGT2B10, UGT2B11, Skp2, EZH2, MDM2, BIRC5 (Survivin), UBE2C, and Smads 1/5/8, which are all associated with the abovementioned key oncogenic pathways, may play critical roles in the putative oncogenic function of JAB1 in PCa.
|
31434609 |
2019 |
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We genotyped 6 single nucleotide polymorphisms in 6 genes, including p53 (rs1042522), p21 (rs1801270), MDM2 (rs2279744), PTEN (rs701848), GNAS1 (rs7121) and bcl2 (rs2279115), using polymerase chain reaction-restriction fragment length polymorphism and direct DNA sequencing in 140 patients with prostate cancer and 167 age matched controls.
|
19237173 |
2009 |
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MDM2 309GG variant was at reduced risk for developing CaP (P = 0.041; OR, 0.59).
|
20822933 |
2012 |